DEFA14A: Anteris Postpones Special Stockholder Meeting

Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders by one week to allow for broader participation and additional voting time.

Summary

• Anteris Technologies Global Corp. announced the postponement of its Special Meeting of Stockholders, originally scheduled for September 11, 2025.
• The Special Meeting is now scheduled to be held virtually on Thursday, September 18, 2025, at 5:00 p.m. Central time (8:00 a.m. AEST on September 19, 2025).
• The postponement aims to provide stockholders with additional time to vote and facilitate broader participation.
• The record date for the Special Meeting, August 11, 2025, remains unchanged.
• The Company's Board of Directors unanimously recommends voting FOR the proposals identified in the definitive Proxy Statement filed on August 18, 2025.
• New proxy submission deadlines are September 17, 2025, for Internet/telephone and mail proxies, and September 16, 2025, for CDI Voting Instruction Forms.

Sentiment

Score: 5

Explanation: The filing is a procedural announcement regarding a meeting postponement. While the need for delay could be seen as a minor negative, the stated reason of facilitating broader participation is a positive governance action, resulting in a neutral overall sentiment.

Positives

• The Board of Directors unanimously recommends voting FOR the proposals, indicating internal alignment.
• The postponement is intended to facilitate broader stockholder participation, demonstrating a commitment to corporate governance and shareholder engagement.

Negatives

• The necessity to postpone the meeting to ensure broader participation could imply that initial stockholder engagement or voting turnout was lower than desired, potentially signaling a challenge in securing sufficient votes or quorum.

Risks

• Uncertainties related to the presence of a quorum at the Special Meeting.
• Uncertainties related to the receipt of stockholder approval of the proposals presented at the Special Meeting.
• General risks described in Anteris' Annual Report on Form 10-K filed on March 12, 2025 (as amended April 29, 2025), and Quarterly Reports on Form 10-Q filed on May 13, 2025, and August 11, 2025.

Future Outlook

The company faces uncertainties regarding achieving a quorum at the Special Meeting and securing stockholder approval for the proposals. The postponement is a measure to mitigate these uncertainties by encouraging broader participation.

Management Comments

• The Company's Board of Directors unanimously recommends that you vote FOR the proposals identified in the Company's definitive Proxy Statement for the Special Meeting.

Industry Context

Anteris Technologies Global Corp. operates in the structural heart medical device industry, focusing on designing, developing, and commercializing cutting-edge devices like the DurAVR Transcatheter Heart Valve (THV) for conditions such as aortic stenosis. The company leverages its patented ADAPT tissue technology, which has a decade of clinical use and has been used in over 55,000 patients worldwide.

Corporate Governance

Stakeholder Impact

• Shareholders: Provided additional time to review proposals and cast votes, potentially increasing participation rates.
• Board of Directors: Actively working to ensure sufficient quorum and approval for the proposals, reflecting their commitment to the agenda.

Next Steps

• Stockholders are urged to read the definitive Proxy Statement and any amendments or supplements.
• Stockholders who have not yet voted should submit their proxies by the new deadlines (September 17, 2025, for Internet/telephone/mail; September 16, 2025, for CDIs).
• The Special Meeting will be held virtually on September 18, 2025.

Key Dates

Recommendation

This filing is a procedural update concerning the postponement of a stockholder meeting, not containing new financial results, operational performance, or strategic shifts. The delay is aimed at improving shareholder participation, which is a neutral to slightly positive governance action. There is no information to warrant a change in an existing investment recommendation.

Keywords

Anteris Technologies, AVR, Special Meeting, Stockholders, Proxy Statement, Corporate Governance, Medical Devices, Structural Heart, DurAVR, ADAPT tissue, NASDAQ, ASX